Sentinus LLC Sells 3,286 Shares of Pfizer Inc. (NYSE:PFE)

Sentinus LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 25.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,710 shares of the biopharmaceutical company’s stock after selling 3,286 shares during the quarter. Sentinus LLC’s holdings in Pfizer were worth $258,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of PFE. Park Avenue Securities LLC increased its stake in Pfizer by 11.4% during the 4th quarter. Park Avenue Securities LLC now owns 106,050 shares of the biopharmaceutical company’s stock valued at $2,814,000 after purchasing an additional 10,824 shares in the last quarter. Tallon Kerry Patrick acquired a new position in Pfizer during the 4th quarter valued at approximately $509,000. Empirical Asset Management LLC increased its stake in Pfizer by 383.4% during the 4th quarter. Empirical Asset Management LLC now owns 49,622 shares of the biopharmaceutical company’s stock valued at $1,316,000 after purchasing an additional 39,356 shares in the last quarter. Wealthcare Advisory Partners LLC increased its stake in Pfizer by 1.5% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 155,044 shares of the biopharmaceutical company’s stock valued at $4,113,000 after purchasing an additional 2,324 shares in the last quarter. Finally, Walker Asset Management LLC increased its stake in Pfizer by 4.6% during the 4th quarter. Walker Asset Management LLC now owns 11,598 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 513 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $22.83 on Friday. The company’s fifty day moving average price is $23.65 and its 200 day moving average price is $25.34. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a market capitalization of $129.77 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the firm posted $0.82 earnings per share. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.